Philips and Indica collaboration accelerates cancer research
January 21, 2015
Philips has increased support for oncology researchers’ efforts to analyse pathology samples by offering advanced image analysis algorithms from Indica Labs. The collaboration will let pathology researchers apply intelligent algorithms to digitised pathology slides, which may enhance their ability to detect, process and extract information from tissue samples than possible using a conventional microscope.
Cancer causes about 15 per cent of deaths worldwide. As the current cancer care process is often complex, inefficient and ineffective, there is a growing need to empower pathologists with quantitative data to inform personalised approaches and enable new cancer treatments.
“Digital pathology is the stepping stone to unlock the huge potential of data mining,” said Perry van Rijsingen, general manager of digital pathology at Dutch company Philips. “More information from tissue samples could bring new insights in cancer care that support personal treatment, and ultimately will save patients’ lives.”
Image analysis, when based on high-quality digital images, has been shown to provide objective data sets for decision support. By using the combined Philips digital pathology products and Indica’s Halo image analysis platform, researchers can benefit from a streamlined image analysis workflow and improved productivity. Additionally, they will be able to extract more thorough information from tissue samples, enabling more insightful analysis than possible today – all while generating those results in a matter of hours or even minutes versus days.
“Digital pathology offers significant opportunity to arm scientists in oncology and pathology with the quantitative information they need in their research to improve the cancer care process,” said Steven Hashagen, CEO of New Mexico based Indica. “By incorporating the high-quality innovation of Philips’ digital imaging and our precision Halo analysis platform, they have the tools to further investigate the predictive response of certain therapy with the ultimate goal to provide a personalised cancer treatment plan.”
Philips research customers will have access to a flexible investigational toolset to develop new systems, as well as a suite of software features for evaluating such cases as HER2, ER PR and Ki-67. Philips is offering Indica’s Halo as an option with its digital pathology for research use products.